Neuropathy is a common finding in patients with multiple myeloma. Several different factors can cause neuropathy in these patients, such as the underlying disease itself, medications used for treatment, or immune-mediated processes. Immune-mediated neuropathies (IMN) consist of a heterogeneous spectrum of peripheral nerve disorders. Although IMN is associated with several hematological disorders, it remains a very rare complication of hematopoietic stem cell transplantation (HCT). We describe our experiences of 3 patients with multiple myeloma who experienced IMN following autologous HCT (auto-HCT). These 3 patients were felt to have IMN clearly attributable to auto-HCT because of a clear temporal association with auto-HCT and absence of any other obvious causative factor. The variety in their clinical presentations, diagnostic approach, and approaches to management are explained. The pathophysiology of how HCT may predispose to IMN remains poorly understood. Our report helps highlight several potential causes of this phenomenon, such as a paraneoplastic syndrome, immune reconstitution syndrome, or drug toxicity. We emphasize that a comprehensive approach is needed to address this rare entity, and that there should be a low threshold to initiate immune-specific therapy, such as plasmapheresis, if symptoms do not resolve spontaneously.

Keywords:
Hematopoietic stem cell transplantation, Multiple myeloma, Immune-mediated neuropathies
1.
Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M: Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica 2010;95:311-319.
2.
Karam C, Mauermann ML, Johnston PB, Lahoria R, Engelstad JK, Dyck PJ: Immune-mediated neuropathies following stem cell transplantation. J Neurol Neurosurg Psychiatry 2014;85:638-642.
3.
Lehmann HC, Meyer Zu Horste G, Kieseier BC, Hartung HP: Pathogenesis and treatment of immune-mediated neuropathies. Ther Adv Neurol Disord 2009;2:261-281.
4.
So YT: Immune-mediated neuropathies. Continuum 2012;18:85-105.
5.
Khadilkar SV, Deshmukh SS, Dhonde PD: Chronic dysimmune neuropathies: beyond chronic demyelinating polyradiculoneuropathy. Ann Indian Acad Neurol 2011;14:81-92.
6.
Amato AA, Barohn RJ, Sahenk Z, Tutschka PJ, Mendell JR: Polyneuropathy complicating bone marrow and solid organ transplantation. Neurology 1993;43:1513-1518.
7.
Rodriguez V, Kuehnle I, Heslop HE, Khan S, Krance RA: Guillain-Barré syndrome after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;29:515-517.
8.
Openshaw H: Peripheral neuropathy after bone marrow transplantation. Biol Blood Marrow Transplant 1997;3:202-209.
9.
Delios AM, Rosenblum M, Jakubowski AA, DeAngelis LM: Central and peripheral nervous system immune mediated demyelinating disease after allogeneic hemopoietic stem cell transplantation for hematologic disease. J Neurooncol 2012;110:251-256.
10.
Grisold W, Cavaletti G, Windebank AJ: Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol 2012;14(suppl 4):iv45-iv54.
11.
Mathew RM, Rosenfeld MR: Neurologic complications of bone marrow and stem-cell transplantation in patients with cancer. Curr Treat Options Neurol 2007;9:308-314.
12.
Najera JE, Sudhakar T, Bashir Q, Shah N, Champlin RE, Qazilbash MH, Giralt S, Hosing C, Popat UR, Ciurea SO: Neurotoxicity after high-dose melphalan. 2012 ASCO Annual Meeting (abstract). J Clin Oncol 2012;30:6546.
13.
Moreau P, Facon T, Attal M, Hulin C, Michallet M, Maloisel F, Sotto JJ, Guilhot F, Marit G, Doyen C, Jaubert J, Fuzibet JG, Francois S, Benboubker L, Monconduit M, Voillat L, Macro M, Berthou C, Dorvaux V, Pignon B, Rio B, Matthes T, Casassus P, Caillot D, Najman N, Grosbois B, Bataille R, Harousseau JL: Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial. Blood 2002;99:731-735.
14.
Palumbo A, Bringhen S, Bruno B, Falcone AP, Liberati AM, Grasso M, Ria R, Pisani F, Cangialosi C, Caravita T, Levi A, Meloni G, Nozza A, Pregno P, Gabbas A, Callea V, Rizzo M, Annino L, De Stefano V, Musto P, Baldi I, Cavallo F, Petrucci MT, Massaia M, Boccadoro M: Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood 2010;115:1873-1879.
15.
Ali AK: Peripheral neuropathy and Guillain-Barré syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis. Ann Epidemiol 2014;24:279-285.
16.
Etminan M, Brophy JM, Samii A: Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study. Neurology 2014;83:1261-1263.
17.
Ravaglia S, Corso A, Piccolo G, Lozza A, Alfonsi E, Mangiacavalli S, Varettoni M, Zappasodi P, Moglia A, Lazzarino M, Costa A: Immune-mediated neuropathies in myeloma patients treated with bortezomib. Clin Neurophysiol 2008;119:2507-2512.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.